ReviewInternational journal of biological sciences2016
Insights into the
Review in International journal of biological sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 62 citations in OpenAlex.
- Liver progenitor cells perform wound healing in a scratch assay by concerted bistable circuits.NPJ systems biology and applications · 2026Article
- Blood Serum From Obese Women Raises ROS Production by Neural Stem Cells.Developmental neurobiology · 2026Article
- Review
- Stable self-assembled oral metformin-bridged nanocochleates against hepatocellular carcinoma.Drug delivery and translational research · 2025Article
- Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance.Journal of hematology & oncology · 2025Review
- PGC7 maintains the pluripotency of F9 embryonic carcinoma cells by promoting Nanog translation.Acta biochimica et biophysica Sinica · 2025Article
- Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises.Stem cell research & therapy · 2025Review
- TREM1 is essential for maintaining stemness of liver cancer stem-like cells in hepatocellular carcinoma.Frontiers in immunology · 2025Article
- Review
- A novel investigation of NANOG and POU5F1 associations in the pluripotent characterization of ES-like and epiblast cells.Scientific reports · 2024Article
- Characterizing CD133 and NANOG Expression in Melanoma: Associations with Histological and Epidemiological Parameters.Medicina (Kaunas, Lithuania) · 2024Article
- Review
- Research progress of nanog gene in fish.Molecular genetics and genomics : MGG · 2024Review
- Article
- Article
- Potential Target of CDK6 Signaling Pathway for Cancer Treatment.Current drug targets · 2024Review
- FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.Science China. Life sciences · 2023Article
- Co-effects of m6A and chromatin accessibility dynamics in the regulation of cardiomyocyte differentiation.Epigenetics & chromatin · 2023Article
- Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer.International journal of molecular sciences · 2023Review
- SPINOPHILIN: A multiplayer tumor suppressor.Genes & diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Self-renewal and pluripotency are two major characteristics of embryonic stem cells (ESCs) that allow ESCs to maintain stem cell population, and differentiate into multiple types of adult tissues. Nanog is the key transcription factor that controls both self-renewal and pluripotency of ESCs. Similarly, cancer stem cells (CSCs) are capable of preserving population and initiating new tumor development by self-renewal. Expression of Nanog family proteins can be increased in many types of cancer which is correlated with tumor outcomes. In this review we summarized the recent understanding of the roles and mechanisms of Nanog in ESC regulation under physiological conditions. In addition, we describe the function of Nanog family proteins in different types of cancer, and the association of Nanog with clinical outcomes. Taken together, Nanog proteins are central regulators controlling both ESCs and CSCs, and are considered as a prognostic marker in many types of cancer. These findings supported the possibility of novel therapeutic potentials of Nanog against cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.